Three Combinations Of Docetaxel And Irinotecan For Recurrent Or Metastatic Non Small Cell Lung Cancer
Status:
Completed
Trial end date:
2006-06-01
Target enrollment:
Participant gender:
Summary
A multicenter randomized phase II study evaluating the activity and tolerability of three
different combinations of docetaxel (taxotere) and irinotecan (campto) as second line therapy
for recurrent or metastatic non small cell lung cancer (NSCLC)